Patient-Centered Treatment Transitions in HR+/HER2− mBC

The panel discusses the patient experience when transitioning between therapies and routes of administration in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2− mBC). NP Kathryn Post emphasizes that moving from a long-standing oral regimen to intramuscular or intravenous therapy can represent a significant decision point, particularly for patients who prioritize quality of life, convenience, and minimizing treatment-related toxicity. She highlights the importance of preparing patients in advance for potential changes in treatment, including discussing efficacy, adverse effects, visit burden, and what options may be considered if the next therapy is ineffective or poorly tolerated. Dr. Jennifer Hutchinson describes a multidisciplinary approach to treatment initiation, involving pharmacy, nursing, advanced practice providers, physicians, patients, and caregivers in detailed education about treatment expectations and toxicity management. The panel also identifies treatment-related toxicity as a key barrier to adherence and stresses proactive education, early communication, and supportive care. Throughout the discussion, maintaining quality of life while helping patients remain engaged and adherent to therapy is emphasized as a central component of care for HR+/HER2− mBC.